Enliven Therapeutics (NASDAQ:ELVN) Stock Price Up 4.5% – Should You Buy?

Enliven Therapeutics, Inc. (NASDAQ:ELVN)’s share price was up 4.5% during trading on Thursday . The stock traded as high as $22.36 and last traded at $22.22. Approximately 122,911 shares were traded during mid-day trading, a decline of 47% from the average daily volume of 230,251 shares. The stock had previously closed at $21.25.

Analysts Set New Price Targets

Several equities analysts have commented on ELVN shares. Robert W. Baird upped their price target on Enliven Therapeutics from $32.00 to $40.00 and gave the company an “outperform” rating in a report on Friday, November 15th. BTIG Research started coverage on Enliven Therapeutics in a report on Friday, December 13th. They issued a “buy” rating and a $42.00 price target for the company. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $38.25.

Enliven Therapeutics Trading Down 2.1 %

The stock has a fifty day moving average price of $21.84 and a 200-day moving average price of $23.88. The firm has a market capitalization of $1.03 billion, a price-to-earnings ratio of -11.05 and a beta of 1.04.

Insider Transactions at Enliven Therapeutics

In related news, COO Anish Patel sold 6,667 shares of the firm’s stock in a transaction on Friday, February 7th. The stock was sold at an average price of $21.93, for a total transaction of $146,207.31. Following the completion of the sale, the chief operating officer now directly owns 329,977 shares of the company’s stock, valued at $7,236,395.61. This trade represents a 1.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Benjamin Hohl sold 3,250 shares of the firm’s stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $20.41, for a total value of $66,332.50. Following the sale, the chief financial officer now directly owns 13,000 shares of the company’s stock, valued at $265,330. This represents a 20.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 41,117 shares of company stock valued at $949,435. Corporate insiders own 29.20% of the company’s stock.

Institutional Investors Weigh In On Enliven Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Enliven Therapeutics by 67.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 43,714 shares of the company’s stock valued at $984,000 after purchasing an additional 17,546 shares in the last quarter. Stempoint Capital LP acquired a new stake in Enliven Therapeutics during the 4th quarter valued at $2,176,000. Polar Capital Holdings Plc increased its holdings in Enliven Therapeutics by 267.6% during the 4th quarter. Polar Capital Holdings Plc now owns 2,389,668 shares of the company’s stock valued at $53,768,000 after purchasing an additional 1,739,668 shares in the last quarter. ProShare Advisors LLC increased its holdings in Enliven Therapeutics by 29.5% during the 4th quarter. ProShare Advisors LLC now owns 12,229 shares of the company’s stock valued at $275,000 after purchasing an additional 2,788 shares in the last quarter. Finally, Patient Square Capital LP increased its holdings in Enliven Therapeutics by 147.4% during the 4th quarter. Patient Square Capital LP now owns 224,038 shares of the company’s stock valued at $5,041,000 after purchasing an additional 133,466 shares in the last quarter. 95.08% of the stock is owned by institutional investors and hedge funds.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.